For pharmaceutical manufacturers, FDA compliance challenges often become visible only after they begin disrupting operations, delaying product commercialization, increasing regulatory exposure, or creating unexpected financial obligations.      Inaccurate establishment registrations, missed reporting deadlines, or gaps in understanding GDUFA and OMUFA requirements can lead to avoidable compliance risks, facility fee complications, import delays, heightened FDA scrutiny, and,…

FDA's Modernization of Cosmetics Regulation Act (MoCRA) is reshaping cosmetic labeling requirements in the United States. As new requirements take effect and additional guidance emerges, cosmetic companies must understand what information belongs on product labels and how to prepare for compliance. Join Registrar Corp's regulatory experts for a practical review of MoCRA labeling requirements, including…